Teduglutide for the treatment of adults with intestinal failure associated with short bowel syndrome: pooled safety data from four clinical trials.

Ther Adv Gastroenterol · 2020 · PMC7171995 · PMID 32341691

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a possible trendno p-value reported

In the RCT teduglutide group, rates of TEAEs of infections and infestations indicated a possible trend for occurring more commonly in patients with baseline PS volume >18 l/week [ n = 10/14 (71.4%)] compared with patients with baseline PS volume ⩽9 l/week [ n = 25/42 (59.5%)].

also in 1,410 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.